Subscribe

Quality of Life Drives Patient Preference for Metastatic RCC Drug

Pazopanib winner in head-to-head QOL comparison
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective - Renal-Cell Carcinoma
Wayne Kuznar

Chicago, IL—The surprising results of the head-to-head randomized clinical trial PISCES on patient preference for one cancer therapy over another show that patient-reported quality-of-life (QOL) differences influence treatment preference far more than physicians had imagined, suggested researchers at ASCO 2012.

In a double-blind, crossover trial, 168 patients with metastatic renal-cell carcinoma (mRCC) were randomized 1:1 to 10 weeks of 800 mg of pazopanib or 50 mg of sunitinib as first-line cancer treatment; after a 2-week washout period, patients received 10 weeks of the alternate treatment. The primary end point was patient preference, measured at 22 weeks.

Because patients with mRCC re­ceive therapies for many months or even years, the researchers assessed whether the drug’s toxicity would be significant enough to make patients want to continue treatment with either drug or to switch therapy.

A total of 126 patients completed a preference questionnaire. In the primary analysis, 70% of the patients preferred pazopanib, 22% preferred sunitinib, and 8% cited no preference. After adjustments for a modest sequence effect, the difference in preference was 49% in favor of pazopanib. All other analyses showed a significant preference for pazopanib.

The most common reasons given for pazopanib preference were better QOL and less fatigue. Patients taking pazopanib had fewer dose reductions than those taking sunitinib (13% vs 20%, respectively) and fewer treatment interruptions (6% vs 12%, respectively). Ad­verse events (AEs) were compatible with known profiles for both drugs.

The researchers, led by Bernard J. Escudier, MD, from the Institut Gustave Roussy, Villejuif, France, said that they expected patients to prefer one drug over the other because of adverse effects, but “we didn’t ever expect such a big difference between the 2 drugs.”

Physicians may perceive toxicity differences between 2 different therapies as relatively minor, but to patients, even low-grade toxicities over a long period have a significant effect on QOL, according to Dr Escudier and colleagues. How patients feel when they take a drug over many months is not reflected in traditional AE reporting.

A survey on physician therapy preferences, which was a secondary end point in this study, showed some difference in physicians’ drug preferences: 60% preferred pazopanib, 21% preferred sunitinib, and 21% had no preference.

Patient-reported outcomes are in­creasingly being added to traditional efficacy outcomes to better understand the clinical relevance of differences in drug toxicities, Dr Escudier and colleagues noted.
 

Related Items
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Renal-Cell Carcinoma
Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective published on August 29, 2012 in Renal-Cell Carcinoma
Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective published on August 29, 2012 in Renal-Cell Carcinoma
First-Line Treatments for Metastatic Renal-Cell Carcinoma Are Evolving
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective published on August 29, 2012 in Renal-Cell Carcinoma
Last modified: August 30, 2012
Copyright © Engage Healthcare Communications, LLC. All rights reserved.